ArticleJournal of clinical microbiology2025
Development and validation of a blocking ELISA for measurement of rabies virus neutralizing antibody.
Article in Journal of clinical microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Enzyme-linked immunosorbent assay (ELISA) is an effective approach for monitoring herd immunity of animals against rabies but not recommended to detect neutralizing antibody response of individual animals in the framework of international travel since its insufficient agreement with the globally recognized rabies virus (RABV) neutralizing tests. In this study, a blocking ELISA to specifically detect anti-RABV neutralizing antibody was developed using the purified RABV glycoprotein (G) expressed in HEK293T cells as coating antigen, and a labeled anti-G neutralizing monoclonal antibody as the blocking antibody. The overall agreement between the blocking ELISA and fluorescent antibody virus neutralization test in detection of clinical serum samples (dogs = 658; cats = 508) was 97.43% (1,136/1,166), with a diagnostic specificity of 95.63% (219/229) and a diagnostic sensitivity of 97.87% (917/937). Further comparison with the commercial ELISA kits and inter-laboratory validation showed that the blocking ELISA had excellent specificity, sensitivity, and reproducibility. In conclusion, the developed method is a potential tool as an alternative to the virus neutralization test for the detection of canine and feline rabies neutralization antibodies following vaccination.IMPORTANCEThis study establishes a blocking enzyme-linked immunosorbent assay (ELISA) for detecting rabies neutralizing antibodies in dogs and cats, demonstrating high sensitivity, specificity, and no cross-reactivity. This method provides a reliable alternative to conventional neutralization assays, facilitating efficient large-scale rabies vaccination assessment, and thereby strengthening global rabies control efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.